Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Flu Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Inactivated Influenza A/H5N1 Vaccine in the Elderly

NCT00230750
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
4
States / cities
Torrance, California • Rochester, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 23, 2026, 7:49 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450
View directory record Official record
Conditions
Viral Lung Infection and Acute Respiratory Failure
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Not applicable Interventional Results available

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625
View directory record Official record
Conditions
Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
Interventions
N95 Respirator, Medical/surgical mask
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
2,862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

NCT00765076
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

NCT01712984
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
38
States / cities
Hoover, Alabama • Huntsville, Alabama • Chandler, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 23, 2026, 7:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

NCT00885105
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 11 Months
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
6
States / cities
Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

NCT02369159
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
0 Days to 17 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Shreveport, Louisiana • Dayton, Ohio • Smithfield, Pennsylvania + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

NCT00566345
View directory record Official record
Conditions
Influenza
Interventions
Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline
Biological · Other
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
3,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151
View directory record Official record
Conditions
Influenza
Interventions
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

NCT01258530
View directory record Official record
Conditions
Influenza, Human
Interventions
over-encapsulated oseltamivir, oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

NCT01175122
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
H2N3 MO 2003/AA ca Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

NCT02624219
View directory record Official record
Conditions
Avian Influenza, Influenza
Interventions
AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

NCT05566639
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Fluarix Quadrivalent
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
22,502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
134
States / cities
Athens, Alabama • Glendale, Arizona • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Epidemic Influenza Through a School-based Influenza Vaccination Program

NCT00138294
View directory record Official record
Conditions
Influenza
Interventions
live attenuated and inactivated influenza vaccines
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years to 18 Years
Enrollment
29,255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2010
U.S. locations
2
States / cities
Temple, Texas • Waco, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 23, 2026, 7:49 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853
View directory record Official record
Conditions
Healthy Adults
Interventions
Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mobile, Alabama • Walnut Creek, California • Milford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 4 Interventional

Randomized Influenza Vaccine Evaluation of Immune Response

NCT03598439
View directory record Official record
Conditions
Influenza
Interventions
Standard IIV4, Recombinant, Cell-culture
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

NCT00730457
View directory record Official record
Conditions
Influenza
Interventions
VAX125
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

NCT02035696
View directory record Official record
Conditions
Influenza
Interventions
Trivalent influenza vaccine (TIVc), Trivalent influenza vaccine-licensed
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 48 Months
Enrollment
671 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Xofluza-Wearables Feasibility-Study

NCT06161454
View directory record Official record
Conditions
Infection, Coronavirus, Infections, Influenza, Transplant, Infection Viral
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
498 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 23, 2026, 7:49 AM EDT
Not listed Phase 4 Interventional

Optimizing Influenza Vaccination in Surgical Oncology Patients

NCT01698177
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 23, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age

NCT00128167
View directory record Official record
Conditions
Influenza
Interventions
Liquid CAIV-T
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 59 Months
Enrollment
8,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
107
States / cities
Hoover, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 23, 2026, 7:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

NCT07610967
View directory record Official record
Conditions
COVID-19 Respiratory Infection, Influenza
Interventions
RD-X19, RD-X19 Sham
Device
Lead sponsor
David Moss
Federal
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 7:49 AM EDT